Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

RELIEF THERAPEUTICS HOLDING AG

(RLF)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

EQS-News : Relief and Applied Pharma Research (APR) Sign Binding Term Sheet for Relief to Acquire All Outstanding Shares of APR

05/04/2021 | 01:02am EDT
EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Acquisition 
Relief and Applied Pharma Research (APR) Sign Binding Term Sheet for Relief to Acquire All Outstanding Shares of APR 
2021-05-04 / 07:00 
=---------------------------------------------------------------------------------------------------------------------- 
Relief and Applied Pharma Research (APR) Sign Binding Term Sheet for Relief to Acquire All Outstanding Shares of APR 
Acquisition would further diversify Relief's pipeline with both commercial products and clinical-stage programs 
Geneva and Balerna, Switzerland, May 4, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF)("Relief"), a 
biopharmaceutical company with its lead compound RLF-100^TM (aviptadil) in advanced clinical development to treat 
COVID-19-induced lung injury, and APR Applied Pharma Research S.A. ("APR"), a privately held Swiss pharmaceutical 
company with over 25 years' experience in identifying, developing and commercializing known molecules engineered with 
drug delivery systems in niche and rare diseases on a global basis, today announced that the companies have signed a 
binding term sheet ("Term Sheet") for Relief to acquire all outstanding shares of APR. 
According to the Term Sheet, the APR shareholders will receive from Relief at the closing of a signed transaction, CHF 
22 million in cash, plus additional cash relating to APR's working capital position at time of close, and CHF 50 
million payable in Relief common registered shares. The APR shareholders are also eligible to receive additional 
contingent payments in the form of a combination of cash and Relief common registered shares upon achievement of 
pre-agreed contingent milestones. In addition, as part of the transaction, an individual to-be-named will stand for 
election as APR's designee at Relief's Annual General Meeting of Shareholders scheduled for June 18, 2021. For a period 
of 60 days, Relief has the exclusive right to negotiate and close the transaction on the basis of the terms and 
conditions in the signed Term Sheet. Further details are not being disclosed at this time. The acquisition of APR is 
expected to be immediately accretive to Relief's earnings and should provide Relief with a reliable platform for future 
growth, including established commercial infrastructure that will facilitate future therapeutic product launches in key 
European markets. 
APR is applying advanced patented pharma technologies, as well as proprietary delivery systems and novel dosage forms, 
to optimize the therapeutic potential of pharmaceuticals and improve patient outcomes. Its products are commercialized 
in about 50 countries worldwide. APR's pipeline and portfolio include products for the treatment of rare or 
debilitating diseases. APR is, for example, commercializing Golike^(R) to improve metabolic control in patients 
suffering from phenylketonuria, a rare genetic metabolic disorder. A direct sales and marketing team is in place in 
selected European countries to support Golike^(R), as well as established distribution partnerships for other countries 
in Europe and beyond. APR also has a strong pipeline of programs in development, including two orphan drug 
designations. Additionally, Sentinox(TM), an intranasal spray to help block the transmission of the SARS-CoV-2 virus, 
just recently received clearance as a Class III medical device in the EU. 
Raghuram (Ram) Selvaraju, Chairman of the Board of Relief, said, "We are pleased to sign this Term Sheet with APR to 
take the next important strategic step in our pipeline expansion plan. From fighting or preventing life-threatening 
lung disease, including that induced by COVID-19, with RLF-100(TM), to effectively addressing patient compliance for 
serious genetic metabolic disorders with ACER-001, we are building a pipeline of products that have the potential to 
truly impact patient lives through improved efficacy, safety or patient convenience. With APR's products already on the 
market, the acquisition will provide Relief with commercial revenues and, importantly, give us access to an established 
commercial organization in key European markets that we hope to leverage for other Relief programs. In addition, we 
will gain a robust clinical portfolio in rare or debilitating diseases with high unmet medical need that is synergistic 
with our current development pipeline." 
Paolo Galfetti, Chief Executive Officer of APR, said, "We are excited about the possibility of joining Relief as they 
share our enthusiasm for our technology and product portfolio and are driven by the goal of helping patients in 
desperate need of better treatment options. This acquisition would provide us greater access to funding and 
international support as we continue to build a commercial infrastructure for our marketed products, as well as work to 
advance our product pipeline as quickly as possible to reach patients." 
### 
ABOUT RELIEF THERAPEUTICS HOLDING AG 
Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in 
human patients or a strong scientific rationale. Relief's lead drug candidate RLF-100^TM (aviptadil), a synthetic form 
of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory 
deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a 
Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of 
ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate 
(NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease. 
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB 
under the symbol RLFTF. 
Follow us on LinkedIn. 
ABOUT APR APPLIED PHARMA RESEARCH S.A. 
APR is an independent pharma company headquartered in Switzerland with subsidiaries in Italy and Germany focused, since 
more than 25 years, in the development and commercialization of products intended to improve the quality of life of 
patients and families dealing with serious diseases of high medical need. APR leverages many years of experience in 
developing patented drug delivery technologies, which are then applied to develop innovative therapeutic solutions. 
APR's portfolio includes products for the treatment of rare or niche diseases which are commercialized in about 50 
countries worldwide either directly or through licensing and distribution agreements with selected partners. The 
pipeline includes products at different stage of development concentrated in 3 selected therapeutic areas: inherited 
metabolic recessive diseases, cancer supportive care and skin rare diseases. For more information, please visit: https: 
//www.apr.ch/ 
APR's investors include well-known life sciences specialist HBM BioCapital II. 
 
CORPORATE CONTACTS 
RELIEF THERAPEUTICS Holding AG:       APR Applied Pharma Research S.A.: 
Jack Weinstein                        Paolo Galfetti 
Chief Financial Officer and Treasurer Chief Executive Officer 
contact@relieftherapeutics.com        info@apr.ch 
                                      +41 91 6957020 
MEDIA CONTACT 
Relief: 
Anne Hennecke 
MC Services AG 
relief@mc-services.eu 
+49 (0) 211-529-252-22 
 
INVESTOR RELATIONS CONTACT 
Relief: 
Anne Hennecke 
MC Services AG 
relief@mc-services.eu 
+49 (0) 211-529-252-22 

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, including (i) whether Relief's acquisition of APR will be completed; (ii) whether any of the drugs in APR's or Relief's pipeline will be approved for commercialization; (iii) whether the acquisition of APR, if completed, will be accretive to Relief; (iv) whether the combined companies will be successful; and (v) those other risks reported in Relief's public filings, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. -----------------------------------------------------------------------------------------------------------------------

End of Media Release -----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      RELIEF THERAPEUTICS Holdings AG 
              Avenue de Sécheron 15 
              1202 Genève 
              Switzerland 
E-mail:       contact@relieftherapeutics.com 
Internet:     https://relieftherapeutics.com 
ISIN:         CH0100191136 
Listed:       SIX Swiss Exchange 
EQS News ID:  1191973 
 
End of News   EQS Group News Service 
=------------ 

1191973 2021-05-04

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1191973&application_name=news 
 

(END) Dow Jones Newswires

May 04, 2021 01:01 ET (05:01 GMT)

All news about RELIEF THERAPEUTICS HOLDING AG
05/04RELIEF THERAPEUTICS  : Signs Binding Term Sheet To Buy APR Applied Pharma Resear..
MT
05/04RELIEF THERAPEUTICS  : and Applied Pharma Research (APR) Sign Binding Term Sheet..
PU
05/04EQS-NEWS  : Relief and Applied Pharma Research (APR) Sign Binding Term Sheet for..
DJ
04/22RELIEF THERAPEUTICS  : Initiates Phase-Two Trial For Respiratory Distress Syndro..
MT
04/22RELIEF THERAPEUTICS  : and AdVita Announce Initiation of Phase 2 Trial with Inha..
PU
04/22RELIEF THERAPEUTICS  : and AdVita Announce Initiation of Phase 2 Trial with Inha..
EQ
04/19RELIEF THERAPEUTICS  : Swiss pharma firm Relief, U.S. partner fight after hopes ..
RE
04/19RELIEF THERAPEUTICS  : Refutes NeuroRx's Claims Over Collaboration Deal
MT
04/19RELIEF THERAPEUTICS  : Comments on Certain Statements Made by NeuroRx, Inc. in t..
PU
04/19RELIEF THERAPEUTICS  : Comments on Certain Statements Made by NeuroRx, Inc. in t..
EQ
More news
Financials
Sales 2021 260 M 289 M 289 M
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 682 M 755 M 757 M
Capi. / Sales 2021 2,62x
Capi. / Sales 2022 1,36x
Nbr of Employees 10
Free-Float 47,8%
Chart RELIEF THERAPEUTICS HOLDING AG
Duration : Period :
Relief Therapeutics Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RELIEF THERAPEUTICS HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 1
Average target price 0,93 CHF
Last Close Price 0,20 CHF
Spread / Highest target 360%
Spread / Average Target 360%
Spread / Lowest Target 360%
Managers and Directors
NameTitle
Jack M. Weinstein Chief Financial Officer & Treasurer
Raghuram Selvaraju Chairman
Gilles Della Corte Chief Medical Officer
Jeremy Meinen Vice President-Finance & Administration
Thomas Plitz Director
Sector and Competitors
1st jan.Capitalization (M$)
RELIEF THERAPEUTICS HOLDING AG-24.91%755
MODERNA, INC.56.17%65 346
LONZA GROUP AG1.51%47 533
IQVIA HOLDINGS INC.30.82%44 923
CELLTRION, INC.-25.77%32 687
SEAGEN INC.-20.36%25 314